Haemonetics (NYSE:HAE) Price Target Raised to $90.00

Haemonetics (NYSE:HAE) had its price objective increased by Barrington Research from $86.00 to $90.00 in a research note published on Friday morning,Benzinga reports. Barrington Research currently has an outperform rating on the medical instruments supplier’s stock. Barrington Research also issued estimates for Haemonetics’ Q3 2026 earnings at $1.27 EPS, Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $4.93 EPS, Q1 2027 earnings at $1.21 EPS, Q2 2027 earnings at $1.43 EPS, Q3 2027 earnings at $1.40 EPS, Q4 2027 earnings at $1.42 EPS, FY2027 earnings at $5.45 EPS and FY2028 earnings at $6.00 EPS.

A number of other research firms also recently weighed in on HAE. Citigroup reduced their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. BTIG Research upped their price objective on shares of Haemonetics from $85.00 to $88.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC lifted their target price on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Friday. Mizuho cut their price objective on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Finally, Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $78.50.

Haemonetics Stock Up 3.7%

HAE stock traded up $2.55 during trading on Friday, reaching $70.91. The stock had a trading volume of 529,196 shares, compared to its average volume of 847,308. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $3.42 billion, a price-to-earnings ratio of 21.68, a P/E/G ratio of 0.91 and a beta of 0.43. Haemonetics has a one year low of $47.31 and a one year high of $94.99. The company’s 50 day moving average is $51.53 and its two-hundred day moving average is $62.13.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts forecast that Haemonetics will post 4.55 EPS for the current year.

Hedge Funds Weigh In On Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd bought a new position in Haemonetics during the 1st quarter valued at approximately $468,000. AQR Capital Management LLC raised its holdings in shares of Haemonetics by 591.6% during the first quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock valued at $10,931,000 after acquiring an additional 149,325 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Haemonetics by 16.0% in the first quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier’s stock worth $3,543,000 after acquiring an additional 7,678 shares during the period. Royal Bank of Canada boosted its holdings in Haemonetics by 2.3% in the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock valued at $68,355,000 after acquiring an additional 24,650 shares in the last quarter. Finally, Invenomic Capital Management LP purchased a new position in Haemonetics during the 1st quarter valued at $6,783,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.